Although response rates were higher in platinum naïve setting [42, 43], these studies were performed in non-selected populations and as such the role of PIK3CA or PTEN alterations in predicting response to mTOR inhibitors in HNSCC is not clearly known. The gene discussed is PTEN; the disease is head and neck squamous cell carcinoma.